Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application

ABSTRACT: The oncolytic rodent protoparvovirus H-1PV has been successfully used in phase I/II clinical trials to treat recurrent glioblastoma multiforme and pancreatic cancer. The present work focuses on the stability and environmental safety of the H-1PV drug product from production up to its use i...

Descripción completa

Detalles Bibliográficos
Autores principales: Frehtman, Veronika, Wohlfarth, Daniel, Müller, Marcus, Krebs, Ottheinz, Leuchs, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Biotechnological Products and Process Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345020/
https://www.ncbi.nlm.nih.gov/pubmed/37209160
http://dx.doi.org/10.1007/s00253-023-12521-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345020/
https://www.ncbi.nlm.nih.gov/pubmed/37209160
http://dx.doi.org/10.1007/s00253-023-12521-4

Ejemplares similares